Glaxo on the slide after trials setback for asthma drug – Evening Standard


Reuters UK

Glaxo on the slide after trials setback for asthma drug
Evening Standard
But clinical trials have not shown the new treatment to be better than GSK's flagship asthma drug Advair. "The results aren't a home run but look adequate for filing and approval," said pharma analyst Emmanuel Papadakis at Collins Stewart.
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies MarketWatch (press release)
GSK to seek approval of Theravance lung drugSan Francisco Business Times (blog)
For COPD, Glaxo intends to submit regulatory applications in the US and Europe ShareCast
Reuters UK –Healthcare Global
all 37 news articles »

View full post on asthma – Google News

Many Patients With Asthma Do Not Respond to Standard Therapy – Medscape

Many Patients With Asthma Do Not Respond to Standard Therapy
Medscape
January 6, 2012 — Approximately one half of patients with mild-to-moderate asthma are unlikely to respond to currently available anti-inflammatory therapy because they have persistently noneosinophilic disease, according to the results of a
Study Offers Clues to Why Some Don't Benefit From Asthma DrugsU.S. News & World Report
A large subgroup of mild-to-moderate asthma is persistently non-eosinophilicEurekAlert (press release)

all 7 news articles »

View full post on asthma – Google News

Asthma sufferer Cathy dreams of completing the London Marathon – Ely Standard


Ely Standard

Asthma sufferer Cathy dreams of completing the London Marathon
Ely Standard
A WICKEN student with severe asthma is aiming to take part in the London Marathon next year. To send a link to this page to a friend, simply enter their email address below. The message will include the name and email address you gave us when you
Inspired by brave ChelseyHaverhill Echo

all 2 news articles »

View full post on asthma – Google News